BORTEZOMİB-LENALİDOMİD-DEKSAMETAZON(VRD) PROTOKOLÜ

Kaynaklar:

1-Richardson PG, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–686.

2- Kumar SK, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010;24:1350–1356.

3-Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–527.

4-Greipp PR, et al. International staging system for multiple myeloma. J. Clin. Oncol. 2005;23:3412–3420.

5- Palumbo A, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 2015;33:2863–2869.